Skip to main content
POLI8
Clinical Investors Contact DE EN Request demo

Data protection

Privacy policy

Data Controller

Caps & Collars GmbH, Geschwister-Scholl-Straße 23, 20251 Hamburg, Managing Director: Oliver Rößling, info@capsncollars.com

Erhebung und Speicherung personenbezogener Daten

When you visit this website, information of a general nature is automatically collected. This information (server log files) includes, for example, the type of web browser, the operating system used, the domain name of your Internet service provider, your IP address and similar. This is primarily necessary for a secure and smooth operation of the website.

Kontaktaufnahme

If you send us inquiries by e-mail or contact form, your details will be stored for the purpose of processing the inquiry and for follow-up questions for two years. We do not pass on this data without your consent.

Cookies

This website does not use cookies. There is no tracking by third parties.

Analyse-Tools

This website does not use analytics tools. No data is transmitted to third parties.

Ihre Rechte

You have the right to receive information free of charge about your stored personal data, its origin and recipients, and the purpose of data processing, as well as the right to correction, blocking, or deletion of this data. You can contact us at any time regarding this or other questions about personal data.

DSGVO

The processing of personal data is based on Art. 6 GDPR. This privacy policy complies with the requirements of the European General Data Protection Regulation (GDPR).

POLI8

The Safe Second Look for Oncology.

Caps & Collars GmbH
Heimhuder Straße 56
20148 Hamburg

Compliance

  • EU AI Act
  • MDR Klasse IIa
  • GDPR
  • ISO 13485
  • ISO 14971

Product

  • FHIR R4
  • RAG / Audit
  • Human-in-the-Loop
  • ESMO ELCAP
  • S3-Leitlinien

Partners

  • Caps & Collars
  • Uroviva
  • VEIL.AI
  • ARIC

Legal

  • Imprint
  • Privacy

POLI8 is a brand of Caps & Collars GmbH, Hamburg. The founding of the POLI8 entity in Zug (Switzerland) is planned for Q1 2026, upon completion of the pre-seed round.